*Risk group assignment according to the BFM 2000 protocol (BFM-ALL Study Group): SR indicates standard risk (prednisolone good response, as well as complete cytomorphologic bone marrow remission on day 33, and neither BCR/ABL nor MLL/AF4, and MRD-negative on day 33); MR, medium risk (as standard but MRD-positive on day 33); HR, high risk (prednisolone poor response or BCR/ABL or MLL/AF4 or MRD-positive on day 77). †Molecular diagnosis included ploidy determination by standard karyotyping, detection of BCR/ABL, E2A/PBX1, MLL-1/AF-4, TEL/AML, SIL/TAL translocations by PCR and reconfirmation by in situ hybridization.
‡Risk assignment according to MRD (minimal residual disease) detection by T-cell receptor or immunoglobulin rearrangement-specific PCR. §CD marker expression in 80% or more of blasts as determined by direct immunofluorescence and FACS analysis. Entity assignment by gene clustering according to Ross et al 33 ( Figure S2 ). ¶GC bioactivity in nM cortisol equivalents: means of 2 measurements at 0, 6, and 24 hours. #Data derived from expression profiling only.
Erratum
In the article by Schmidt et al entitled "Identification of glucocorticoidresponse genes in children with acute lymphoblastic leukemia," which appeared in the March 1, 2006, issue of Blood (Volume 107:2061-2069), Table 2 contained inaccurate information about the sex of patient B-ALL-24, the immunophenotypes of patient B-ALL-32, and most of the GBA values. The corrected Table 2 
